Please use this identifier to cite or link to this item: https://covid-19.conacyt.mx/jspui/handle/1000/7267
Persistence of neutralizing antibodies a year after SARS-CoV-2 infection
Anu Haveri
Nina Ekstrom
Anna Solastie
Camilla Virta
Pamela Österlund
Elina Isosaari
Hanna Nohynek
Arto Palmu
Merit Melin
Acceso Abierto
Atribución-NoComercial-SinDerivadas
https://doi.org/10.1101/2021.07.13.21260426
https://www.medrxiv.org/content/10.1101/2021.07.13.21260426v1
Understanding for how long antibodies persist following Severe acute respiratory coronavirus 2 (SARS-CoV-2) infection provides important insight into estimating the duration of immunity induced by infection. We assessed the persistence of serum antibodies following wild-type SARS-CoV-2 infection six and twelve months after diagnosis in 367 individuals of whom 13% had severe disease requiring hospitalization. We determined the SARS-CoV-2 spike (S-IgG) and nucleoprotein IgG concentrations and the proportion of subjects with neutralizing antibodies (NAb). We also measured the NAb titers among a smaller subset of participants (n=78) against a wild-type virus (B.1) and three variants of concern (VOCs): Alpha (B.1.1.7), Beta (B.1.351) and Delta (B.1.617.2). We found that NAb against the wild-type virus and S-IgG persisted in 89% and 97% of subjects for at least twelve months after infection, respectively. IgG and NAb levels were higher after severe infection. NAb titers were significantly lower against variants compared to the wild-type virus.
medRxiv
13-07-2021
Preimpreso
www.medrxiv.org
Inglés
Epidemia COVID-19
Público en general
VIRUS RESPIRATORIOS
Versión publicada
publishedVersion - Versión publicada
Appears in Collections:Artículos científicos

Upload archives